dextroamphetamine has been researched along with Hyperactivity, Motor in 210 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 7.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| " Evaluation of (+)-22a in animal models of schizophrenia-related behaviors revealed that it had a desirable activity profile, as it reduced d-amphetamine-stimulated hyperlocomotion in the open field test, it restored d-amphetamine-disrupted prepulse inhibition, it induced cognitive improvements in the novel object recognition memory test in NR1-KD animals, and it produced very little catalepsy relative to haloperidol." | 3.83 | Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. ( Cheng, J; Giguere, PM; Huang, XP; Kozikowski, AP; McCorvy, JD; Pogorelov, VM; Rodriguiz, RM; Roth, BL; Schmerberg, CM; Wetsel, WC; Zhu, H, 2016) |
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 3.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| " We studied the effect of SB-271046 [5-chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide], a specific 5-HT(6) receptor antagonist, in three models for the positive symptoms of schizophrenia---D-amphetamine-induced hyperactivity, and D-amphetamine- or phencyclidine (PCP)-disrupted prepulse inhibition (PPI)." | 3.71 | Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia. ( Arnt, J; Didriksen, M; Pouzet, B, 2002) |
| "The relative bioavailability of oral lisdexamfetamine dimesylate, a prodrug of d-amphetamine, and active d-amphetamine was assessed in an open-label, single-dose, 3-treatment, 3-period, randomized, crossover study in 18 healthy adult volunteers." | 2.73 | Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. ( Krishnan, S; Zhang, Y, 2008) |
| " By measuring the brain function using computer period analysis of cerebral biopotentials, dose-efficacy relations were found (in the range of 25-75 mcg) which suggest the bioavailability of LHM at the CNS level." | 2.64 | Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram. ( Akpinar, S; Herrmann, WM; Itil, TM, 1975) |
| "Chlorpromazine was effective for the majority of the children, but reduced only hyperactivity, having no demonstrable effect on distractibility, aggressivity or excitability." | 2.64 | Comparison of the effects of chlorpromazine, dextroamphetamine and methylphenidate on the behaviour and intellectual functioning of hyperactive children. ( Douglas, V; Minde, K; Sykes, D; Weiss, G; Werry, J, 1971) |
| " Chronic administration of lithium chloride or valproic acid, two clinically effective mood stabilizers, reverses the majority of these behavioral abnormalities." | 1.42 | Mice heterozygous for cathepsin D deficiency exhibit mania-related behavior and stress-induced depression. ( Duan, S; Han, Y; Li, X; Lou, H; Lu, Y; Zhen, X; Zhou, R; Zhu, L, 2015) |
| "Propofol treatment (25mg/kg) decreased exon-specific and total BDNF mRNA expression in the frontal cortex and thalamus, in a time-dependent manner." | 1.42 | Neonatal propofol anesthesia modifies activity-dependent processes and induces transient hyperlocomotor response to d-amphetamine during adolescence in rats. ( Jevtović-Todorović, V; Kanazir, S; Milanović, D; Pešić, V; Popić, J; Ruždijić, S; Smiljanić, K; Tešić, V, 2015) |
| " In the present studies, dose-response curves for d-amphetamine (AMPH)-induced hyperlocomotion were similar in standard B6 mice and in the BTBR mouse model of autism." | 1.39 | Influence of stimulant-induced hyperactivity on social approach in the BTBR mouse model of autism. ( Babineau, BA; Crawley, JN; Karras, MN; Oliver, CF; Silverman, JL, 2013) |
| "Cadmium-exposed rats were also less sensitive to the locomotor-activating effect of acute methamphetamine (0." | 1.33 | Dietary cadmium exposure attenuates D-amphetamine-evoked [3H]dopamine release from striatal slices and methamphetamine-induced hyperactivity. ( Casteel, SW; Dopheide, MM; Miller, DK; Smith, SM, 2005) |
| "Ketamine-treated mice showed cell degeneration mainly in the parietal cortex, whereas the Ethanol-High mice showed marked cell degeneration in both the parietal and laterodorsal cortex." | 1.32 | Hyperactivity following postnatal NMDA antagonist treatment: reversal by D-amphetamine. ( Archer, T; Fredriksson, A, 2003) |
| " All three antihistaminics, at some dosage levels, enhanced morphine-induced hyperactivity, but did not change or even reduce locomotor stimulation induced by amphetamine and scopolamine." | 1.27 | Antihistaminics enhance morphine-, but not amphetamine- and scopolamine-induced hyperactivity in mice. ( D'Udine, B; Renzi, P; Sansone, M; Vetulani, J, 1987) |
| "Pretreatment with reserpine (0." | 1.26 | Effects of reserpine and amphetamine on the development of hyperactivity in maternally deprived rat pups. ( Hofer, MA, 1980) |
| "In respect to myoclonus, clonidine persisted in producing effects similar to those seen in the long-sleep mice whereas apomorphine exhibited the same ontogenetic alteration in effect seen with amphetamine." | 1.26 | Paradoxical effects of d-amphetamine upon seizure susceptibility in 2 selectively bred lines of mice. ( Alpern, HP; Greer, CA, 1980) |
| " The combination of a clinically useful medication in appropriate dosage schedules with relevant psychological treatments simultaneously directed to each of the child's many disabilities were associated with an unexpectedly good outcome at the end of one and two years." | 1.26 | Multimodality treatment. A two-year evaluation of 61 hyperactive boys. ( Cantwell, DP; Satterfield, BT; Satterfield, JH, 1980) |
| "Gilles de la Tourette's syndrome was independently ascertained in two male cousins once removed." | 1.26 | Gilles de la Tourette's syndrome. Familial occurrence and precipitation by methylphenidate therapy. ( Cohen, NL; Friedhoff, AJ; Pollack, MA, 1977) |
| " This temporary effect on growth is present during the first few years of treatment and seems related to drug dosage and to the presence or absence of drug holidays." | 1.26 | The effects of stimulant medication on the growth of hyperkinetic children. ( Hung, W; Lipman, RS; Overall, JE; Roche, AF, 1979) |
| "We conclude that phenytoin induced hyperkinesias reflect a specific effect of phenytoin on an abnormal neural substrate and suggest the presence of an otherwise silent pathological alteration of the corpus striatum." | 1.26 | Clinical and experimental studies of phenytoin-induced hyperkinesias. ( Klawans, HL; Koller, WC; Nausieda, PA; Weiner, WJ, 1979) |
| " The acute administration of very low doses of APO (30 microgram/KG; Sc) reduces the behavioral deficits; similarly a chronic administration of d-aMPH (two injections daily for 43 days) reduces locomotor hyperactivity." | 1.26 | Small doses of apomorphine and chronic administration of d-amphetamine reduce locomotor hyperactivity produced by radiofrequency lesions of dopaminergic A10 neurons area. ( Gaffori, O; Le Moal, M; Simon, H; Stinus, L, 1977) |
| "Depression is an important cause of behavioral disturbances in children." | 1.26 | Childhood depression: an explanation of a behavior disorder of children. ( Brumback, RA; Weinberg, WA, 1977) |
| " No correlations were found between dosage level and changes in weight and height percentiles." | 1.26 | Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine. ( Gross, MD, 1976) |
| "Dextroamphetamine treatment substantially reduced the spinal fluid content of homovanillic acid but not of 5-hydroxyindoleacetic acid." | 1.26 | Central monoamines and hyperkinase of childhood. ( Chase, TN; Shetty, T, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 175 (83.33) | 18.7374 |
| 1990's | 2 (0.95) | 18.2507 |
| 2000's | 21 (10.00) | 29.6817 |
| 2010's | 12 (5.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rogóż, Z | 3 |
| Kameda, SR | 2 |
| Fukushiro, DF | 2 |
| Wuo-Silva, R | 2 |
| Trombin, TF | 2 |
| Procópio-Souza, R | 2 |
| Brandão, LC | 1 |
| Sanday, L | 1 |
| Patti, CL | 1 |
| Mári-Kawamoto, E | 1 |
| Tufik, S | 2 |
| D'Almeida, V | 1 |
| Frussa-Filho, R | 2 |
| Steinkellner, T | 1 |
| Mus, L | 1 |
| Eisenrauch, B | 1 |
| Constantinescu, A | 1 |
| Leo, D | 1 |
| Konrad, L | 1 |
| Rickhag, M | 1 |
| Sørensen, G | 1 |
| Efimova, EV | 1 |
| Kong, E | 1 |
| Willeit, M | 1 |
| Sotnikova, TD | 1 |
| Kudlacek, O | 1 |
| Gether, U | 1 |
| Freissmuth, M | 1 |
| Pollak, DD | 1 |
| Gainetdinov, RR | 2 |
| Sitte, HH | 1 |
| Valvassori, SS | 3 |
| Tonin, PT | 1 |
| Varela, RB | 2 |
| Carvalho, AF | 1 |
| Mariot, E | 1 |
| Amboni, RT | 1 |
| Bianchini, G | 1 |
| Andersen, ML | 2 |
| Quevedo, J | 3 |
| Czopek, A | 1 |
| Kołaczkowski, M | 1 |
| Bucki, A | 1 |
| Byrtus, H | 1 |
| Pawłowski, M | 1 |
| Kazek, G | 1 |
| Bojarski, AJ | 1 |
| Piaskowska, A | 1 |
| Kalinowska-Tłuścik, J | 1 |
| Partyka, A | 1 |
| Wesołowska, A | 1 |
| Zhou, R | 1 |
| Lu, Y | 1 |
| Han, Y | 1 |
| Li, X | 1 |
| Lou, H | 1 |
| Zhu, L | 1 |
| Zhen, X | 1 |
| Duan, S | 1 |
| Pešić, V | 1 |
| Milanović, D | 1 |
| Popić, J | 1 |
| Smiljanić, K | 1 |
| Tešić, V | 1 |
| Kanazir, S | 1 |
| Jevtović-Todorović, V | 1 |
| Ruždijić, S | 1 |
| Cheng, J | 1 |
| Giguere, PM | 1 |
| Schmerberg, CM | 1 |
| Pogorelov, VM | 1 |
| Rodriguiz, RM | 1 |
| Huang, XP | 1 |
| Zhu, H | 1 |
| McCorvy, JD | 1 |
| Wetsel, WC | 1 |
| Roth, BL | 1 |
| Kozikowski, AP | 1 |
| van der Staay, FJ | 1 |
| Pouzet, B | 3 |
| Mahieu, M | 1 |
| Nordquist, RE | 1 |
| Schuurman, T | 1 |
| Krapacher, FA | 1 |
| Mlewski, EC | 1 |
| Ferreras, S | 1 |
| Pisano, V | 1 |
| Paolorossi, M | 1 |
| Hansen, C | 1 |
| Paglini, G | 1 |
| Zanlorenci, LH | 1 |
| Lima, AJ | 1 |
| Ribeiro, LT | 1 |
| Corrêa, JM | 1 |
| Marinho, EA | 1 |
| Moretti, M | 1 |
| Ferreira, CL | 1 |
| Rochi, N | 1 |
| Benedet, J | 1 |
| Scaini, G | 1 |
| Kapczinski, F | 2 |
| Streck, EL | 1 |
| Zugno, AI | 1 |
| Silverman, JL | 1 |
| Babineau, BA | 1 |
| Oliver, CF | 1 |
| Karras, MN | 1 |
| Crawley, JN | 1 |
| Vanderschuren, LJ | 1 |
| Beemster, P | 1 |
| Schoffelmeer, AN | 1 |
| ALBANO, G | 1 |
| DIBENEDETTO, A | 1 |
| CRISCUOLI, PM | 1 |
| INDOVINA, T | 1 |
| CANDIA, A | 1 |
| CIULLA, C | 1 |
| Fredriksson, A | 1 |
| Archer, T | 1 |
| Leng, A | 1 |
| Feldon, J | 1 |
| Ferger, B | 1 |
| Isacson, R | 1 |
| Kull, B | 1 |
| Wahlestedt, C | 1 |
| Salmi, P | 1 |
| Expósito-Orta, MA | 1 |
| Albertos, LM | 1 |
| Darias, V | 1 |
| Sánchez-Mateo, CC | 1 |
| Pietraszek, M | 1 |
| Wolfarth, S | 1 |
| Ossowska, K | 1 |
| McDougall, SA | 1 |
| Hernandez, RM | 1 |
| Reichel, CM | 1 |
| Farley, CM | 1 |
| Miller, DK | 2 |
| Dopheide, MM | 1 |
| Smith, SM | 1 |
| Casteel, SW | 1 |
| Kusljic, S | 1 |
| van den Buuse, M | 1 |
| Siuciak, JA | 1 |
| Chapin, DS | 1 |
| McCarthy, SA | 1 |
| Guanowsky, V | 1 |
| Brown, J | 1 |
| Chiang, P | 1 |
| Marala, R | 1 |
| Patterson, T | 1 |
| Seymour, PA | 1 |
| Swick, A | 1 |
| Iredale, PA | 1 |
| Gould, TD | 1 |
| O'Donnell, KC | 1 |
| Picchini, AM | 1 |
| Manji, HK | 1 |
| Fadda, P | 1 |
| Bedogni, F | 1 |
| Fresu, A | 1 |
| Collu, M | 1 |
| Racagni, G | 1 |
| Riva, MA | 1 |
| Rodvelt, KR | 1 |
| Constales, C | 1 |
| Putnam, WC | 1 |
| Krishnan, S | 1 |
| Zhang, Y | 1 |
| Petronilho, FC | 1 |
| Réus, GZ | 1 |
| Steckert, AV | 1 |
| Oliveira, VB | 1 |
| Boeck, CR | 1 |
| Dal-Pizzol, F | 1 |
| Cools, AR | 3 |
| van Rossum, JM | 1 |
| Smith, DF | 1 |
| Martin, CA | 1 |
| Welsh, RJ | 1 |
| McKay, SE | 1 |
| Bareuther, CM | 1 |
| Swartzwelder, HS | 1 |
| Holahan, W | 1 |
| Myers, RD | 1 |
| Ervin, GN | 1 |
| Schmitz, SA | 1 |
| Nemeroff, CB | 1 |
| Prange, AJ | 1 |
| Schechter, MD | 3 |
| Concannon, JT | 2 |
| Rapoport, JL | 8 |
| Tepsic, PN | 1 |
| Grice, J | 1 |
| Johnson, C | 1 |
| Langer, D | 1 |
| Zahn, TP | 2 |
| Thompson, CL | 1 |
| Nee, L | 1 |
| Mitchell, S | 1 |
| Polinsky, R | 1 |
| Ebert, M | 1 |
| Shekim, WO | 6 |
| Dekirmenjian, H | 5 |
| Javaid, J | 2 |
| Bylund, DB | 1 |
| Davis, JM | 2 |
| Voith, VL | 1 |
| Hofer, MA | 1 |
| Golinko, BE | 1 |
| Rennick, PM | 1 |
| Glaros, AG | 1 |
| Arnold, LE | 8 |
| Greer, CA | 1 |
| Alpern, HP | 1 |
| Buchsbaum, MS | 3 |
| Weingartner, H | 3 |
| Bunney, WE | 2 |
| Ebert, MH | 5 |
| Mikkelsen, EJ | 4 |
| Caine, ED | 1 |
| DeVeaugh-Geiss, J | 1 |
| Joseph, A | 1 |
| Brown, GL | 4 |
| Hunt, RD | 3 |
| Brown, RT | 1 |
| Greenhill, LL | 4 |
| Puig-Antich, J | 3 |
| Halpern, F | 1 |
| Sachar, EJ | 3 |
| Rubinstein, B | 1 |
| Chambers, W | 1 |
| Fiscina, B | 1 |
| Florea, J | 1 |
| Satterfield, JH | 2 |
| Satterfield, BT | 1 |
| Cantwell, DP | 1 |
| Ludlow, C | 1 |
| Gardner, RA | 1 |
| Blanc, G | 2 |
| Trovero, F | 1 |
| Vezina, P | 1 |
| Hervé, D | 1 |
| Godeheu, AM | 1 |
| Glowinski, J | 2 |
| Tassin, JP | 2 |
| Maj, J | 1 |
| Skuza, G | 1 |
| Darracq, L | 1 |
| Drouin, C | 1 |
| Andersen, MP | 1 |
| Mohn, AR | 1 |
| Bohn, LM | 1 |
| Caron, MG | 1 |
| Lessenich, A | 1 |
| Lindemann, S | 1 |
| Richter, A | 1 |
| Hedrich, HJ | 1 |
| Wedekind, D | 1 |
| Kaiser, A | 1 |
| Löscher, W | 1 |
| Didriksen, M | 1 |
| Arnt, J | 1 |
| Lambert, NM | 2 |
| Windmiller, M | 1 |
| Sandoval, J | 2 |
| Moore, B | 1 |
| Bhatara, V | 1 |
| Knopp, W | 3 |
| Smeltzer, DJ | 3 |
| Kopin, IJ | 2 |
| Bareggi, SR | 1 |
| Becker, RE | 1 |
| Ginsburg, B | 1 |
| Genovese, E | 1 |
| Pycock, CJ | 1 |
| Horton, RW | 1 |
| Livingston, S | 2 |
| Pruce, I | 1 |
| Pauli, LL | 2 |
| Livingston, HL | 1 |
| Cole, SO | 2 |
| Silver, LB | 2 |
| Krager, JM | 2 |
| Safer, D | 3 |
| Earhart, J | 1 |
| Pollack, MA | 1 |
| Cohen, NL | 1 |
| Friedhoff, AJ | 1 |
| Codd, JA | 1 |
| Aarskog, D | 1 |
| Fevang, FO | 1 |
| Klove, H | 1 |
| Stoa, KF | 1 |
| Thorsen, T | 1 |
| Sells, CJ | 2 |
| Eaton, M | 1 |
| Lucas, B | 2 |
| Wolraich, ML | 1 |
| Margolin, DI | 1 |
| Williams, JI | 1 |
| Cram, DM | 1 |
| Tausig, FT | 1 |
| Webster, E | 1 |
| Christopher, J | 1 |
| Huestis, R | 1 |
| Barkley, RA | 2 |
| Cunningham, CE | 1 |
| Feinberg, M | 1 |
| Carroll, BJ | 1 |
| Swidler, HJ | 1 |
| Walson, PD | 1 |
| Chapel, JL | 5 |
| Roche, AF | 1 |
| Lipman, RS | 1 |
| Overall, JE | 1 |
| Hung, W | 1 |
| Nausieda, PA | 1 |
| Koller, WC | 1 |
| Weiner, WJ | 1 |
| Klawans, HL | 1 |
| Snead, OC | 1 |
| Stinus, L | 1 |
| Gaffori, O | 1 |
| Simon, H | 1 |
| Le Moal, M | 1 |
| Scott, JP | 1 |
| Surwillo, WW | 1 |
| Fisher, MA | 1 |
| O'Leary, SG | 1 |
| Pelham, WE | 1 |
| Sassin, J | 2 |
| Weise, VK | 1 |
| Whalen, CK | 1 |
| Henker, B | 1 |
| Baxley, GB | 1 |
| LeBlanc, JM | 1 |
| Seals, JR | 1 |
| White, JH | 1 |
| Conner, AE | 1 |
| Brumback, RA | 1 |
| Weinberg, WA | 1 |
| Friend, JC | 1 |
| Halpern, WI | 1 |
| Shaywitz, BA | 1 |
| Klopper, JH | 1 |
| Yager, RD | 1 |
| Gordon, JW | 1 |
| Gross, MD | 3 |
| Shetty, T | 3 |
| Chase, TN | 1 |
| Moore, SF | 1 |
| Anonsen, DC | 2 |
| Allen, RP | 5 |
| Covi, L | 1 |
| Costall, B | 2 |
| Kelly, DM | 1 |
| Naylor, RJ | 2 |
| Itil, TM | 2 |
| Herrmann, WM | 1 |
| Akpinar, S | 1 |
| Schain, RJ | 1 |
| Springer, NS | 1 |
| Fricke, NL | 1 |
| Safer, DJ | 5 |
| Barr, E | 2 |
| Minde, KK | 1 |
| Rie, HE | 1 |
| Logue, GD | 1 |
| Montagu, JD | 1 |
| Swarbrick, L | 1 |
| Sulzbacher, SI | 1 |
| Weithorn, CJ | 1 |
| Ross, R | 1 |
| Stableford, W | 1 |
| Butz, R | 1 |
| Leitenberg, H | 1 |
| Peyser, J | 1 |
| Yandell, W | 1 |
| Akins, K | 1 |
| Borcherding, BG | 1 |
| Keysor, CS | 1 |
| Cooper, TB | 1 |
| Sansone, M | 1 |
| D'Udine, B | 1 |
| Renzi, P | 1 |
| Vetulani, J | 1 |
| Solomons, G | 1 |
| Van Osdol, BM | 1 |
| Carlson, L | 1 |
| Campbell, M | 2 |
| Breuer, H | 1 |
| Wolman, SR | 1 |
| Faigel, HC | 1 |
| Sarma, PS | 1 |
| Falk, MA | 1 |
| Feighner, AC | 1 |
| Feighner, JP | 1 |
| Davies, C | 1 |
| Sanger, DJ | 1 |
| Steinberg, H | 2 |
| Tomkiewicz, M | 2 |
| U'Prichard, DC | 1 |
| Small, A | 1 |
| Hibi, S | 1 |
| Feinberg, I | 1 |
| Newell, GR | 1 |
| Henderson, BE | 1 |
| Millichap, JG | 1 |
| Ounsted, C | 1 |
| Eisenberg, L | 3 |
| Conners, CK | 3 |
| Taylor, E | 1 |
| Meo, G | 1 |
| Kurtz, MA | 1 |
| Fournier, M | 1 |
| Winsberg, BG | 2 |
| Bialer, I | 3 |
| Kupietz, S | 3 |
| Tobias, J | 1 |
| Allen, R | 1 |
| Greenberg, LM | 1 |
| Deem, MA | 1 |
| McMahon, S | 1 |
| Wender, PH | 2 |
| McCloskey, K | 1 |
| Snyder, SH | 1 |
| Kirilcuk, V | 1 |
| Corson, SA | 1 |
| Corson, EO | 1 |
| Rieder, RO | 1 |
| Buchsbaum, M | 1 |
| Zhan, TP | 1 |
| Forman, MA | 1 |
| Hetznecker, W | 1 |
| Fish, B | 1 |
| David, R | 1 |
| Shapiro, T | 1 |
| Collins, P | 1 |
| Koh, C | 1 |
| Press, M | 1 |
| Sleator, EK | 1 |
| Von Neumann, A | 1 |
| Sprague, RL | 1 |
| Simeon, J | 1 |
| Omenn, GS | 1 |
| Strobl, D | 1 |
| Weisenberg, A | 1 |
| Green, RP | 1 |
| Scales, SM | 1 |
| Rosser, PL | 1 |
| Chapple, PA | 1 |
| Ullrich, JR | 1 |
| Chinoy, MP | 1 |
| Andras, RL | 1 |
| O'Malley, JE | 1 |
| Fras, I | 1 |
| Case, Q | 1 |
| McAndrew, JB | 1 |
| Hoeffler, DF | 1 |
| Silbergeld, EK | 1 |
| Goldberg, AM | 1 |
| Weiss, G | 4 |
| Werry, J | 2 |
| Minde, K | 3 |
| Douglas, V | 2 |
| Sykes, D | 2 |
| Rothschild, G | 1 |
| Schwartz, LS | 1 |
| Robinson, E | 1 |
| Kornetsky, C | 1 |
| Steinberg, GG | 1 |
| Troshinsky, C | 1 |
| Steinberg, HR | 1 |
| Barkai, A | 1 |
| Winsberg, HG | 1 |
| Mendelson, N | 1 |
| McCabe, ER | 1 |
| McCabe, L | 1 |
| Erenberg, G | 1 |
| Howell, MC | 1 |
| Rever, GW | 1 |
| Scholl, ML | 1 |
| Trowbridge, F | 1 |
| Rutledge, A | 1 |
| Dawson, ME | 1 |
| Finnerty, RJ | 1 |
| Soltys, JJ | 1 |
| Cole, JO | 1 |
| Cox, C | 1 |
| Harrison-Read, PE | 1 |
| Rapoport, J | 1 |
| Abramson, A | 1 |
| Alexander, D | 1 |
| Lott, I | 1 |
| Barcai, A | 2 |
| Scanlon, J | 1 |
| Olsen, R | 1 |
| Anton, AH | 1 |
| Greer, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection)[NCT01777542] | Phase 2 | 30 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD and Substance Use Disorder[NCT02477280] | Phase 4 | 39 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD[NCT02473185] | Phase 4 | 40 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Pediatric Attention Deficit Hyperactivity Disorder: Predicting Clinical Response to Stimulant Medication From Single-dose Changes in Event Related Potentials[NCT02695355] | Phase 2 | 87 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The ABC-C is a global behavior checklist implemented for the measurement of drug and other treatment effects in populations with intellectual disability. Behavior based on 58 items that describe various behavioral problems.~Each item is rated on the parents perceived severity of the behavior. The answer options for each item are:~0 = Not a problem~= Problem but slight in degree~= Moderately serious problem~= Severe in degree~The measure is broken down into the following subscales with individual ranges as follows:~Subscale I (Irritability): 15 items, score range = 0-45 Subscale II (Lethargy): 16 items, score range = 0-48 Subscale III (Stereotypy): 7 items, score range = 0-21 Subscale IV (Hyperactivity): 16 items, score range = 0-48 Subscale V (Inappropriate Speech) was not included in the breakdown because it was not applicable (no participants in the study had verbal language)." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Subscale I | Visit 3 - First Intervention: Subscale I | Visit 5 - First Intervention: Subscale I | Visit 6 - Second Intervention: Subscale I | Visit 8 - Second Intervention: Subscale I | Visit 10 - Second Intervention: Subscale I | Follow-up: Subscale I (Irritability) | Visit 1 - First Intervention: Subscale II | Visit 3 - First Intervention: Subscale II | Visit 5 - First Intervention: Subscale II | Visit 6 - Second Intervention: Subscale II | Visit 8 - Second Intervention: Subscale II | Visit 10 - Second Intervention: Subscale II | Follow-up: Subscale II (Lethargy) | Visit 1 - First Intervention: Subscale III | Visit 3 - First Intervention: Subscale III | Visit 5 - First Intervention: Subscale III | Visit 6 - Second Intervention: Subscale III | Visit 8 - Second Intervention: Subscale III | Visit 10 - Second Intervention: Subscale III | Follow-up: Subscale III (Stereotypy) | Visit 1 - First Intervention: Subscale IV | Visit 3 - First Intervention: Subscale IV | Visit 5 - First Intervention: Subscale IV | Visit 6 - Second Intervention: Subscale IV | Visit 8 - Second Intervention: Subscale IV | Visit 10 - Second Intervention: Subscale IV | Follow-up: Subscale IV (Hyperactivity) | |
| Placebo First, Then rhIGF-1 | 9.00 | 9.00 | 7.00 | 7.00 | 4.00 | 5.00 | 3.00 | 13.00 | 11.00 | 9.00 | 11.00 | 8.00 | 6.00 | 6.00 | 13.00 | 10.00 | 11.00 | 11.00 | 10.00 | 8.00 | 8.00 | 13.00 | 12.00 | 11.00 | 11.00 | 7.00 | 10.00 | 9.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 2.00 | 4.00 | 3.00 | 5.00 | 2.00 | 8.00 | 7.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.00 | 12.00 | 10.00 | 9.00 | 11.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 6.00 | 7.00 | 4.00 | 5.00 | 5.00 |
"Remaining subscales of the ADAMS that are not primary outcome measures include: Manic/hyperactive, Depressed mood, General anxiety, Obsessive/compulsive behavior.~The range for each subscale is as follows:~Manic/Hyperactive Behavior: 0-15 Depressed Mood: 0-21 General Anxiety: 0-21 Obsessive/Compulsive Behavior: 0-9~The higher the score for each subscale, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Manic/Hyperactive | Visit 2- First Intervention: Manic/Hyperactive | Visit 3- First Intervention: Manic/Hyperactive | Visit 4- First Intervention: Manic/Hyperactive | Visit 5- First Intervention: Manic/Hyperactive | Visit 6- Second Intervention: Manic/Hyperactive | Visit 7- Second Intervention: Manic/Hyperactive | Visit 8- Second Intervention: Manic/Hyperactive | Visit 9- Second Intervention: Manic/Hyperactive | Visit 10- First Intervention: Manic/Hyperactive | Follow-up: Manic/Hyperactive Subscale | Visit 1- First Intervention: Depressed Mood | Visit 2- First Intervention: Depressed Mood | Visit 3- First Intervention: Depressed Mood | Visit 4- First Intervention: Depressed Mood | Visit 5- First Intervention: Depressed Mood | Visit 6- Second Intervention: Depressed Mood | Visit 7- Second Intervention: Depressed Mood | Visit 8- Second Intervention: Depressed Mood | Visit 9- Second Intervention: Depressed Mood | Visit 10- Second Intervention: Depressed Mood | Follow-up: Depressed Mood Subscale | Visit 1- First Intervention: General Anxiety | Visit 2- First Intervention: General Anxiety | Visit 3- First Intervention: General Anxiety | Visit 4- First Intervention: General Anxiety | Visit 5- First Intervention: General Anxiety | Visit 6- Second Intervention: General Anxiety | Visit 7- Second Intervention: General Anxiety | Visit 8- Second Intervention: General Anxiety | Visit 9- Second Intervention: General Anxiety | Visit 10- Second Intervention: General Anxiety | Follow-up: General Anxiety Subscale | Visit 1- First Intervention: Obsessive Compulsive | Visit 2- First Intervention: Obsessive Compulsive | Visit 3- First Intervention: Obsessive Compulsive | Visit 4- First Intervention: Obsessive Compulsive | Visit 5- First Intervention: Obsessive Compulsive | Visit 6- Second Intervention: Obsessive Compulsive | Visit 7- Second Intervention: Obsessive Compulsive | Visit 8- Second Intervention: Obsessive Compulsive | Visit 9- Second Intervention: Obsessive Compulsive | Visit 10- First Intervention: Obsessive Compulsive | Follow-up: Obsessive Compulsive Behavior Subscale | |
| Placebo First, Then rhIGF-1 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 8.00 | 6.50 | 6.00 | 6.00 | 5.00 | 5.00 | 2.00 | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 2.00 | 2.00 | 8.00 | 6.00 | 6.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 4.00 | 4.00 | 5.50 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 7.00 | 7.00 | 6.00 | 5.00 | 4.00 | 6.00 | 5.00 | 5.00 | 4.00 | 4.50 | 5.00 | 4.00 | 5.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 2.00 | 3.00 | 3.50 | 6.00 | 7.00 | 6.00 | 5.00 | 5.00 | 7.00 | 5.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.50 | 3.00 |
"The ADAMS is completed by the parent/caregiver/LAR and consists of 29 items which are scored on a 4-point rating scale that combines frequency and severity ratings. The instructions ask the rater to describe the individual's behavior over the last six months on the following scale: 0 if the behavior has not occurred, 1 if the behavior occurs occasionally or is a mild problem, 2 if the behavior occurs quite often or is moderate problem, or 3 if the behavior occurs a lot or is a severe problem.~The Social Avoidance subscale of the ADAMS will be used as a primary outcome measure for this trial. The range for this subscale is 0-21. The higher the subscale score, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 3.00 |
"Each time the patient was seen after the study intervention was initiated, the clinician compared the patient's overall clinical condition to the CGI-S score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | ||||
|---|---|---|---|---|---|
| Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
"This scale is used to judge the severity of the subject's disease prior to entry into the study. The clinician will rate the severity of behavioral symptoms at baseline on a 7-point scale from not impaired to the most impaired.~The scores that correspond to each possible grouping are as follows: 1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.50 |
"The CSBS-DP was designed to measure early communication and symbolic skills in infants and young children (that is, functional communication skills of 6 month to 2 year olds). The CSBS-DP measures skills from three composites: (a) Social (emotion, eye gaze, and communication); (b) Speech (sounds and words); and (c) Symbolic (understanding and object use) and asks about developmental milestones. The data reported are the composite scores for these three categories.~The possible scores for the three composite categories are as follows:~Social Composite = 0-48; Speech Composite = 0-40; Symbolic Composite = 0-51.~A higher score indicates more advanced abilities in that area." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Social | Visit 2: Social Composite Score | Visit 3: Social Composite Score | Visit 4: Social Composite Score | Visit 5: Social Composite Score | Visit 6 - Second Intervention: Social | Visit 7 - Second Intervention: Social | Visit 8 - Second Intervention: Social | Visit 9 - Second Intervention: Social | Visit 10 - Second Intervention: Social | Follow-up: Social Composite Score | Visit 1 - First Intervention: Speech | Visit 2 - First Intervention: Speech | Visit 3 - First Intervention: Speech | Visit 4 - First Intervention: Speech | Visit 5 - First Intervention: Speech | Visit 6 - Second Intervention: Speech | Visit 7 - Second Intervention: Speech | Visit 8 - Second Intervention: Speech | Visit 9 - Second Intervention: Speech | Visit 10 - Second Intervention: Speech | Follow-up: Speech Composite Score | Visit 1 - First Intervention: Symbolic | Visit 2 - First Intervention: Symbolic | Visit 3 - First Intervention: Symbolic | Visit 4 - First Intervention: Symbolic | Visit 5 - First Intervention: Symbolic | Visit 6 - Second Intervention: Symbolic | Visit 7 - Second Intervention: Symbolic | Visit 8 - Second Intervention: Symbolic | Visit 9 - Second Intervention: Symbolic | Visit 10 - Second Intervention: Symbolic | Follow-up: Symbolic Composite Score | |
| Placebo First, Then rhIGF-1 | 19.00 | 20.00 | 18.00 | 18.00 | 20.00 | 18.00 | 20.00 | 21.00 | 21.00 | 22.50 | 22.50 | 4.00 | 3.00 | 5.00 | 5.50 | 6.50 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 9.50 | 10.50 | 10.50 | 12.00 | 11.50 | 13.00 | 10.25 | 11.50 | 11.50 | 13.75 | 14.25 |
| rhIGF-1 First, Then Placebo | 22.00 | 24.00 | 24.00 | 24.00 | 23.00 | 28.00 | 25.00 | 27.00 | 29.00 | 27.00 | 28.00 | 7.00 | 5.00 | 8.00 | 5.00 | 8.00 | 8.50 | 7.00 | 6.50 | 5.00 | 7.25 | 6.00 | 14.00 | 14.50 | 15.00 | 14.00 | 16.50 | 18.50 | 17.00 | 17.00 | 18.00 | 17.00 | 18.00 |
"The Kerr clinical severity scale (Kerr scale) is a quantitative measure of global disease severity. The Kerr scale is a summation of individual items related to Rett syndrome phenotypic characteristics. The items are based on the severity or degree of abnormality of each characteristic on a discrete scale (0, 1, 2) with the highest level corresponding to the most severe or most abnormal presentations.~The possible range of scores is 0-48. The higher the score, the more severe the symptoms." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 16.50 | 15.00 | 15.00 | 14.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 18.00 | 19.00 | 20.00 |
"The MSEL is a standardized developmental test for children ages 3 to 68 months consisting of five subscales: gross motor, fine motor, visual reception, expressive language, and receptive language.~The raw score is reported for each subscale domain. The potential score ranges are as follows:~Visual Reception: 33 items, score range=0-50, Fine Motor: 30 items, score range= 0-49, Receptive Language: 33 items, score range= 0-48, Expressive Language: 28 items, score range= 0-50. The gross motor subscale was not included in this population.~A higher raw score indicates more advanced abilities in that section." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Visual Reception | Visit 5- First Intervention: Visual Reception | Visit 6- Second Intervention: Visual Reception | Visit 10: Visual Reception Raw Score | Visit 1- First Intervention: Fine Motor | Visit 5- First Intervention: Fine Motor | Visit 6- Second Intervention: Fine Motor | Visit 10- Second Intervention: Fine Motor | Visit 1- First Intervention: Receptive Language | Visit 5- First Intervention: Receptive Language | Visit 6- Second Intervention: Receptive Language | Visit 10- Second Intervention: Receptive Language | Visit 1- First Intervention: Expressive Language | Visit 5- First Intervention: Expressive Language | Visit 6- Second Intervention: Expressive Language | Visit 10- Second Intervention: Expressive Language | |
| Placebo First, Then rhIGF-1 | 17.00 | 26.00 | 23.00 | 28.00 | 10.00 | 9.00 | 11.00 | 9.00 | 20.00 | 30.00 | 31.00 | 31.00 | 8.00 | 9.00 | 6.00 | 8.00 |
| rhIGF-1 First, Then Placebo | 26.00 | 39.50 | 42.00 | 44.00 | 7.00 | 7.00 | 10.00 | 8.50 | 25.50 | 32.00 | 38.00 | 36.50 | 9.00 | 8.00 | 10.00 | 8.00 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.50 | 4.70 | 5.65 | 5.05 | 4.80 | 4.95 | 4.55 | 5.65 | 4.15 | 4.80 | 5.60 |
| rhIGF-1 First, Then Placebo | 8.80 | 4.80 | 5.35 | 5.10 | 5.15 | 5.20 | 4.65 | 5.00 | 5.15 | 5.05 | 5.08 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.75 | 4.50 | 5.85 | 5.00 | 5.00 | 5.35 | 5.50 | 5.15 | 3.80 | 4.90 | 5.15 |
| rhIGF-1 First, Then Placebo | 6.35 | 5.25 | 5.95 | 5.40 | 5.45 | 7.10 | 5.85 | 5.00 | 5.13 | 4.95 | 5.20 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.85 | 4.70 | 5.65 | 4.15 | 5.00 | 6.20 | 4.80 | 4.85 | 4.60 | 4.13 | 4.55 |
| rhIGF-1 First, Then Placebo | 5.70 | 5.00 | 5.20 | 5.35 | 5.10 | 5.35 | 4.95 | 5.15 | 5.25 | 4.55 | 5.10 |
"As part of each visit after the study intervention was initiated, the parent/caregiver was asked to compare the patient's overall clinical condition to the score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
"The PGI-S is the parent version of the CGI-S. Parents/caregivers/LAR are asked to rate the severity of their child's symptoms at baseline on a 7-point scale from not at all impaired to the most impaired. The parents/caregivers/LAR will complete the PGI-S at each study visit.~The scores that correspond to each possible grouping are as follows:~1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 6.00 | 6.00 | 5.00 | 4.00 |
"Respiratory data was collected using non-invasive respiratory inductance plethysmography from a BioCapture® recording device. BioCapture® is a child-friendly measurement device that can record from 1 to 12 physiological signal transducers in a time-locked manner. It can be configured with the pediatric chest and abdominal plethysmography bands and the 3 lead ECG signals we plan to use for monitoring cardiac safety throughout the study. Each transducer is placed on the patient independently to provide a customized fit that yields the highest signal quality for each patient irrespective of body shape and proportion. The transducer signals captured by the BioCapture® are transmitted wirelessly to a laptop computer where all signals are displayed in real-time.~The apnea index is given as apneas/hour. Data on apneas greater than or equal to 10 seconds are displayed below. The higher the frequency of apnea, the more severe the breathing abnormality." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | Apneas/Hour (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Apnea Index | Visit 3 - First Intervention: Apnea Index | Visit 5 - First Intervention: Apnea Index | Visit 6 - Second Intervention: Apnea Index | Visit 8 - Second Intervention: Apnea Index | Visit 10 - Second Intervention: Apnea Index | |
| Placebo First, Then rhIGF-1 | 7.58 | 4.80 | 6.93 | 7.90 | 7.28 | 8.91 |
| rhIGF-1 First, Then Placebo | 4.05 | 3.48 | 3.07 | 3.62 | 5.55 | 5.56 |
"The RSBQ is a parent-completed measure of abnormal behaviors typically observed in individuals with RTT. Each item, grouped into eight subscales, is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of each subscale is reported. The higher the score, the more severe the symptoms of that subscale in the participant.~The range for each subscale is as follows:~General Mood: 0-16 Body rocking and expressionless face: 0-14 Hand behaviors: 0-12 Breathing Problems: 0-10 Repetitive Face Movements: 0-8 Night-time behaviors: 0-6 Walking Standing: 0-4~The fear/anxiety subscale was used as a primary outcome measure in this study and results can be found in that section." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: General Mood | Visit 2- First Intervention: General Mood | Visit 3- First Intervention: General Mood | Visit 4- First Intervention: General Mood | Visit 5- First Intervention: General Mood | Visit 6- Second Intervention: General Mood | Visit 7- Second Intervention: General Mood | Visit 8- Second Intervention: General Mood | Visit 9- Second Intervention: General Mood | Visit 10- Second Intervention: General Mood | Follow-up: General Mood | Visit 1- First Intervention: Body Rocking | Visit 2- First Intervention: Body Rocking | Visit 3- First Intervention: Body Rocking | Visit 4- First Intervention: Body Rocking | Visit 5- First Intervention: Body Rocking | Visit 6- Second Intervention: Body Rocking | Visit 7- Second Intervention: Body Rocking | Visit 8- Second Intervention: Body Rocking | Visit 9- Second Intervention: Body Rocking | Visit 10- Second Intervention: Body Rocking | Followup: Body Rocking | Visit 1- First Intervention: Hand Behaviors | Visit 2- First Intervention: Hand Behaviors | Visit 3- First Intervention: Hand Behaviors | Visit 4- First Intervention: Hand Behaviors | Visit 5- First Intervention: Hand Behaviors | Visit 6- Second Intervention: Hand Behaviors | Visit 7- Second Intervention: Hand Behaviors | Visit 8- Second Intervention: Hand Behaviors | Visit 9- Second Intervention: Hand Behaviors | Visit 10- Second Intervention: Hand Behaviors | Follow-up: Hand Behaviors | Visit 1- First Intervention: Breathing Problems | Visit 2- First Intervention: Breathing Problems | Visit 3- First Intervention: Breathing Problems | Visit 4- First Intervention: Breathing Problems | Visit 5- First Intervention: Breathing Problems | Visit 6- Second Intervention: Breathing Problems | Visit 7- Second Intervention: Breathing Problems | Visit 8- Second Intervention: Breathing Problems | Visit 9- Second Intervention: Breathing Problems | Visit 10- Second Intervention: Breathing Problems | Follow-up: Breathing Problems | Visit 1- First Intervention: Repetitive Face Movem | Visit 2- First Intervention: Repetitive Face Movem | Visit 3- First Intervention: Repetitive Face Movem | Visit 4- First Intervention: Repetitive Face Movem | Visit 5- First Intervention: Repetitive Face Movem | Visit 6- Second Intervention: Repetitive Face Mov | Visit 7- Second Intervention: Repetitive Face Mov | Visit 8- Second Intervention: Repetitive Face Mov | Visit 9- Second Intervention: Repetitive Face Mov | Visit 10- Second Intervention: Repetitive Face Mov | Follow-up: Repetitive Face Movements | Visit 1- First Intervention: Night time Behaviors | Visit 2- First Intervention: Night time Behaviors | Visit 3- First Intervention: Night time Behaviors | Visit 4- First Intervention: Night time Behaviors | Visit 5- First Intervention: Night time Behaviors | Visit 6- Second Intervention: Night time Behavior | Visit 7- Second Intervention: Night time Behavior | Visit 8- Second Intervention: Night time Behavior | Visit 9- Second Intervention: Night time Behavior | Visit 10- Second Intervention: Night time Behavior | Follow-up: Night time Behaviors | Visit 1- First Intervention: Walking/Standing | Visit 2- First Intervention: Walking/Standing | Visit 3- First Intervention: Walking/Standing | Visit 4- First Intervention: Walking/Standing | Visit 5- First Intervention: Walking/Standing | Visit 6- Second Intervention: Walking/Standing | Visit 7- Second Intervention: Walking/Standing | Visit 8- Second Intervention: Walking/Standing | Visit 9- Second Intervention: Walking/Standing | Visit 10- Second Intervention: Walking/Standing | Follow-up: Walking/Standing | |
| Placebo First, Then rhIGF-1 | 7.00 | 5.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.50 | 5.00 | 6.00 | 4.00 | 5.50 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 4.00 | 5.00 | 4.50 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.50 | 6.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 4.50 | 6.00 | 5.00 | 6.00 | 5.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 1.50 | 2.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 4.00 | 2.00 | 2.00 | 1.00 | 2.50 | 2.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 4.00 | 3.00 | 4.00 | 4.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 8.00 | 9.00 | 9.00 | 7.00 | 9.00 | 8.50 | 4.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.50 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
"The RSBQ is an informant/parent-completed measure of abnormal behaviors typically observed in individuals with RTT, which is completed by a parent/caregiver/LAR. Each item, grouped into eight domains/factors: General mood, Breathing problems, Body rocking and expressionless face, Hand behaviors, Repetitive face movements, Night-time behaviors, Fear/anxiety and Walking/standing), is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of items in each subscale is reported.~For the fear/anxiety subscale, the sum total could be between 0-8. The higher the sum total score, the greater the frequency of fear/anxiety behaviors." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 4.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.50 |
"The VABS-II is a survey designed to assess personal and social functioning. Within each domain (Communication, Daily Living Skills, Socialization, and Motor Skills), items can given a score of 2 if the participant successfully performs the activity usually; a 1 if the participant successfully performs the activity sometimes, or needs reminders; a 0 if the participant never performs the activity, and a DK if the parent/caregiver is unsure of the participant's ability for an item.~The raw scores in each sub-domain are reported and the ranges for these are as follows: [Communication Domain], Receptive Language=0-40, Expressive Language=0-108, Written Language=0-50; [Daily Living Skills Domain], Personal=0-82, Domestic=0-48, Community=0-88; [Socialization Domain], Interpersonal Relationships=0-76, Play and Leisure Time=0-62, Coping Skills=0-60; [Motor Skills Domain]: Gross Motor Skills=0-80, Fine Motor Skills=0-72.~A higher score indicates more advanced abilities." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Receptive | Visit 5 - First Intervention: Receptive | Visit 6 - Second Intervention: Receptive Language | Visit 10 - Second Intervention: Receptive Language | Visit 1 - First Intervention: Expressive | Visit 5 - First Intervention: Expressive | Visit 6 - Second Intervention: Expressive Lang. | Visit 10 - Second Intervention: Expressive Lang. | Visit 1 - First Intervention: Written | Visit 5 - First Intervention: Written | Visit 6: - Second Intervention Written Language | Visit 10 - Second Intervention: Written Language | Visit 1 - First Intervention: Personal | Visit 5 - First Intervention: Personal | Visit 6 - Second Intervention: Personal | Visit 10 - Second Intervention: Personal | Visit 1 - First Intervention: Domestic | Visit 5 - First Intervention: Domestic | Visit 6 - Second Intervention: Domestic | Visit 10 - Second Intervention: Domestic | Visit 1 - First Intervention: Community | Visit 5 - First Intervention: Community | Visit 6 - Second Intervention: Community | Visit 10 - Second Intervention: Community | Visit 1 - First Intervention: Interpersonal Rel. | Visit 5 - First Intervention: Interpersonal Rel. | Visit 6 - Second Intervention: Interpersonal Rel. | Visit 10 - Second Intervention: Interpersonal Rel. | Visit 1 - First Intervention: Play and Leisure | Visit 5 - First Intervention: Play and Leisure | Visit 6 - Second Intervention: Play and Leisure | Visit 10 - Second Intervention: Play and Leisure | Visit 1 - First Intervention: Coping Skills | Visit 5 - First Intervention: Coping Skills | Visit 6 - Second Intervention: Coping Skills | Visit 10 - Second Intervention: Coping Skills | Visit 1 - First Intervention: Gross Motor | Visit 5 - First Intervention: Gross Motor | Visit 6 - Second Intervention: Gross Motor | Visit 10 - Second Intervention: Gross Motor | Visit 1 - First Intervention: Fine Motor | Visit 5 - First Intervention: Fine Motor | Visit 6 - Second Intervention: Fine Motor | Visit 10 - Second Intervention: Fine Motor | |
| Placebo First, Then rhIGF-1 | 13.00 | 15.00 | 18.00 | 20.00 | 16.00 | 17.00 | 18.00 | 20.00 | 0.00 | 0.00 | 4.00 | 6.00 | 9.00 | 10.00 | 9.00 | 10.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 2.00 | 18.00 | 18.00 | 19.00 | 20.00 | 8.00 | 11.00 | 12.00 | 11.00 | 3.00 | 2.00 | 3.00 | 4.00 | 31.00 | 34.00 | 27.00 | 27.00 | 6.00 | 6.00 | 7.00 | 5.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 21.00 | 22.00 | 24.50 | 18.00 | 22.00 | 25.00 | 24.00 | 4.00 | 5.00 | 7.00 | 7.00 | 8.00 | 9.00 | 8.50 | 9.50 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 | 5.00 | 5.00 | 21.00 | 22.00 | 21.00 | 22.50 | 13.00 | 12.00 | 13.00 | 12.50 | 3.00 | 4.00 | 6.00 | 4.50 | 10.00 | 10.00 | 11.50 | 10.50 | 2.00 | 3.00 | 4.00 | 4.00 |
21 reviews available for dextroamphetamine and Hyperactivity, Motor
| Article | Year |
|---|---|
Multiple receptors for brain dopamine in behavior regulation: concept of dopamine-E and dopamine-I receptors.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Behavior, Animal; Brain; Cats; Corpus Striatum; Dextroamphe | 1980 |
Hyperactivity (attention-deficit disorder).
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Family; Female; Humans; Hyp | 1984 |
Hyperactive children and the efficacy of psychoactive drugs as a treatment intervention.
Topics: Amphetamines; Central Nervous System Stimulants; Child Behavior; Chlordiazepoxide; Chlorpromazine; C | 1976 |
Hyperkinetic children: the use of stimulant drugs evaluated.
Topics: Achievement; Animals; Attention; Blood Pressure; Central Nervous System; Dextroamphetamine; Feeding | 1975 |
Acceptable and controversial approaches to treating the child with learning disabilities.
Topics: Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Attention; Child; | 1975 |
The hyperkinetic child syndrome and brain monoamines: pharmacology and therapeutic implications.
Topics: Animals; Arousal; Attention; Brain; Child; Dextroamphetamine; Disease Models, Animal; Dopamine; Huma | 1978 |
Hyperactivity: a current assessment.
Topics: Catecholamines; Central Nervous System Agents; Child; Dextroamphetamine; Diet; Food Additives; Food | 1979 |
Psychostimulants and children: a review and analysis.
Topics: Attention; Child; Child Behavior; Cognition; Dextroamphetamine; Drug Evaluation; Humans; Hyperkinesi | 1976 |
Psychostimulants and children: a review and analysis.
Topics: Attention; Child; Child Behavior; Cognition; Dextroamphetamine; Drug Evaluation; Humans; Hyperkinesi | 1976 |
Psychostimulants and children: a review and analysis.
Topics: Attention; Child; Child Behavior; Cognition; Dextroamphetamine; Drug Evaluation; Humans; Hyperkinesi | 1976 |
Psychostimulants and children: a review and analysis.
Topics: Attention; Child; Child Behavior; Cognition; Dextroamphetamine; Drug Evaluation; Humans; Hyperkinesi | 1976 |
The hyperactive child: characteristics, treatment, and evaluation of research design.
Topics: Central Nervous System Diseases; Child; Child Behavior; Dextroamphetamine; Electroencephalography; H | 1976 |
Predicting the response of hyperkinetic children to stimulant drugs: a review.
Topics: Amphetamine; Amphetamines; Child; Clinical Trials as Topic; Dextroamphetamine; Electroencephalograph | 1976 |
MBD: advanced in understanding many bothersome dilemmas.
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool | 1976 |
Effects of psychostimulants on aggression.
Topics: Adolescent; Aggression; Amphetamine; Animals; Child; Dextroamphetamine; Dogs; Dose-Response Relation | 1975 |
Minimal brain Dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Diseases; Cerebral Palsy; Child; Child, Prescho | 1975 |
Nutrition and drug therapy for persons with developmental disabilities.
Topics: Anticonvulsants; Antidepressive Agents; Appetite; Dextroamphetamine; Drug-Related Side Effects and A | 1975 |
A study of developmental hyperactivity.
Topics: Aggression; Antisocial Personality Disorder; Attention; Behavior Therapy; Child; Child Behavior Diso | 1972 |
The growth of children given stimulant drugs.
Topics: Appetite; Body Height; Body Weight; Child; Dextroamphetamine; Dose-Response Relationship, Drug; Educ | 1973 |
Child psychiatry.
Topics: Adolescent; Adoption; Child; Child Abuse; Child Behavior Disorders; Child Development; Child Psychia | 1972 |
Genetic issues in the syndrome of minimal brain dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Dextroamphetamine; Diseases in Twins; Female; Humans; | 1973 |
Psychoactive drugs in the immature organism.
Topics: Amphetamine; Animals; Autistic Disorder; Behavior, Animal; Catecholamines; Child; Child Behavior; Ch | 1970 |
The neurologic learning disability syndrome.
Topics: Anorexia Nervosa; Anxiety; Attention; Attention Deficit Disorder with Hyperactivity; Brain Damage, C | 1971 |
[Stimulants in the treatment of hyperkinetic behavior disorders].
Topics: Amphetamine; Child; Child Behavior Disorders; Child, Preschool; Dextroamphetamine; Humans; Hyperkine | 1971 |
40 trials available for dextroamphetamine and Hyperactivity, Motor
| Article | Year |
|---|---|
Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study.
Topics: Administration, Oral; Adult; Area Under Curve; Biological Availability; Blood Pressure; Capsules; Cr | 2008 |
Decreased motor activity of hyperactive children on dextroamphetamine during active gym program.
Topics: Attention; Child; Dextroamphetamine; Humans; Hyperkinesis; Male; Motor Activity; Physical Education | 1980 |
Autonomic effects of dextroamphetamine in normal men: implications for hyperactivity and schizophrenia.
Topics: Adult; Autonomic Nervous System; Child; Dextroamphetamine; Galvanic Skin Response; Heart Rate; Human | 1981 |
Dextroamphetamine. Its cognitive and behavioral effects in normal and hyperactive boys and normal men.
Topics: Adolescent; Adult; Affect; Attention; Child; Dextroamphetamine; Dose-Response Relationship, Drug; Hu | 1980 |
A survey study of the use of electropupillogram in predicting response to psychostimulants.
Topics: Adolescent; Caffeine; Central Nervous System Stimulants; Child; Child, Preschool; Dextroamphetamine; | 1978 |
The effect of the stimulant drugs, dextroamphetamine and methylphenidate, on secretion of growth hormone in hyperactive children.
Topics: Adolescent; Child; Clinical Trials as Topic; Dextroamphetamine; Female; Growth Hormone; Homeostasis; | 1977 |
Central nervous system stimulants--their use in the "non-classical" hyperkinetic syndrome: a case-controlled study.
Topics: Appetite; Child; Clinical Trials as Topic; Crying; Dextroamphetamine; Humans; Hyperkinesis; Male; Me | 1977 |
Nutrient intake and stimulant drugs in hyperactive children.
Topics: Ascorbic Acid; Calcium, Dietary; Child; Clinical Trials as Topic; Dextroamphetamine; Diet; Dietary P | 1977 |
Stimulant drug therapy in hyperactive children: research and clinical implications.
Topics: Adolescent; Behavior Therapy; Child; Child, Preschool; Clinical Trials as Topic; Dextroamphetamine; | 1977 |
Relative effects of drugs and diet on hyperactive behaviors: an experimental study.
Topics: Adolescent; Child; Child Behavior; Child, Preschool; Clinical Trials as Topic; Dextroamphetamine; Do | 1978 |
Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes' analysis.
Topics: Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Child, Preschool; Clinical Trials as | 1978 |
The effects of methylphenidate on the mother-child interactions of hyperactive children.
Topics: Child; Child Behavior; Child, Preschool; Clinical Trials as Topic; Cooperative Behavior; Dextroamphe | 1979 |
Effects of dopamine agonists and antagonists in Tourette's disease.
Topics: Adolescent; Adult; Amphetamine; Apomorphine; Child; Clinical Trials as Topic; Dextroamphetamine; Dop | 1979 |
Urinary catecholamines and amphetamine excretion in hyperactive and normal boys.
Topics: Amphetamine; Child; Dextroamphetamine; Dopamine; Epinephrine; Homovanillic Acid; Humans; Hyperkinesi | 1978 |
Predicting the response of hyperkinetic children to stimulant drugs: a review.
Topics: Amphetamine; Amphetamines; Child; Clinical Trials as Topic; Dextroamphetamine; Electroencephalograph | 1976 |
Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram.
Topics: Adolescent; Adult; Aged; Biological Availability; Child; Child, Preschool; Clinical Trials as Topic; | 1975 |
Caffeine in the treatment of children with minimal brain dysfunction or hyperkinetic syndrome.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Child, Preschool; Clinic | 1975 |
A comparison of dextro-amphetamine and racemic-amphetamine in the treatment of the hyperkinetic syndrome or minimal brain dysfunction.
Topics: Adolescent; Age Factors; Amphetamine; Attention Deficit Disorder with Hyperactivity; Child; Child, P | 1976 |
Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children.
Topics: Child; Circadian Rhythm; Clinical Trials as Topic; Dextroamphetamine; Double-Blind Method; Humans; H | 1989 |
Magnesium pemoline and dextroamphetamine: a controlled study in children with minimal brain dysfunction.
Topics: Analysis of Variance; Anxiety; Attention; Attention Deficit Disorder with Hyperactivity; Child; Dext | 1972 |
Effects of imipramine and dextroamphetamine on behavior of neuropsychiatrically impaired children.
Topics: Adolescent; Aggression; Anxiety; Brain Damage, Chronic; Child; Child Behavior Disorders; Clinical Tr | 1972 |
Depression of growth in hyperactive children on stimulant drugs.
Topics: Body Height; Body Weight; Child; Clinical Trials as Topic; Dextroamphetamine; Growth; Humans; Hyperk | 1972 |
Effects of dextroamphetamine, chlorpromazine, and hydroxyzine on behavior and performance in hyperactive children.
Topics: Child; Chlorpromazine; Clinical Trials as Topic; Depression; Dextroamphetamine; Dose-Response Relati | 1972 |
Levoamphetamine and dextroamphetamine: comparative efficacy in the hyperkinetic syndrome. Assessment by target symptoms.
Topics: Aggression; Amphetamine; Attention; Body Weight; Child; Clinical Trials as Topic; Dextroamphetamine; | 1972 |
Levoamphetamine and dextroamphetamine: differential effect on aggression and hyperkinesis in children and dogs.
Topics: Aggression; Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; C | 1973 |
Lithium carbonate in the treatment of hyperactive children.
Topics: Administration, Oral; Adolescent; Carbonates; Child; Child Behavior Disorders; Clinical Trials as To | 1973 |
Drug comparison in hyperactive children.
Topics: Child; Chlorpromazine; Clinical Trials as Topic; Dextroamphetamine; Evaluation Studies as Topic; Hum | 1973 |
Liothyronine treatment in psychotic and nonpsychotic children under 6 years.
Topics: Age Factors; Brain Damage, Chronic; Child; Child Behavior Disorders; Child, Preschool; Clinical Tria | 1973 |
Dextroamphetamine and methylphenidate in the treatment of hyperactive-aggressive children.
Topics: Aggression; Anxiety; Attention; Child; Child Behavior Disorders; Child, Preschool; Clinical Trials a | 1974 |
Hyperactive children. A continuous long-term placebo-controlled follow-up.
Topics: Age Factors; Child; Clinical Trials as Topic; Dextroamphetamine; Drug Evaluation; Follow-Up Studies; | 1974 |
Proceedings: Computerized EEG in the prediction of outcome of drug treatment in hyperactive childhood behavior disorders.
Topics: Child; Child Behavior Disorders; Clinical Trials as Topic; Computers; Dextroamphetamine; Electroence | 1974 |
Hyperkinetic adult. Study of the "paradoxical" amphetamine response.
Topics: Adult; Age Factors; Amphetamine; Anxiety; Depression; Dextroamphetamine; Humans; Hyperkinesis; Male; | 1972 |
Studies on the hyperactive child. V. The effects of dextroamphetamine and chlorpromazine on behaviour and intellectual functioning.
Topics: Aggression; Child; Child Behavior Disorders; Chlorpromazine; Clinical Trials as Topic; Dextroampheta | 1968 |
Dextroamphetamine sulfate in children with learning disorders. Effects on perception, learning, and achievement.
Topics: Achievement; Attention; Auditory Perception; Child; Clinical Trials as Topic; Dextroamphetamine; Dis | 1969 |
Psychoactive drugs in the immature organism.
Topics: Amphetamine; Animals; Autistic Disorder; Behavior, Animal; Catecholamines; Child; Child Behavior; Ch | 1970 |
Dextroamphetamine-responsive behavior disorder in school children.
Topics: Attention; Child; Child Behavior Disorders; Child, Preschool; Clinical Trials as Topic; Dextroamphet | 1971 |
Alpha rhythms in the hyperkinetic child.
Topics: Cerebral Cortex; Child; Child, Preschool; Clinical Trials as Topic; Dextroamphetamine; Electroenceph | 1971 |
The use of D-amphetamine with hyperkinetic children.
Topics: Attitude; Child; Child Behavior; Dextroamphetamine; Female; Humans; Hyperkinesis; Intelligence; Inte | 1971 |
Comparison of the effects of chlorpromazine, dextroamphetamine and methylphenidate on the behaviour and intellectual functioning of hyperactive children.
Topics: Child; Child Behavior Disorders; Chlorpromazine; Dextroamphetamine; Female; Humans; Hyperkinesis; Le | 1971 |
Predicting the response of children with learning disabilities and behavior problems to dextroamphetamine sulfate. The clinical interview and the finger twitch test.
Topics: Child; Child Behavior Disorders; Dextroamphetamine; Follow-Up Studies; Hand; Humans; Hyperkinesis; I | 1971 |
151 other studies available for dextroamphetamine and Hyperactivity, Motor
| Article | Year |
|---|---|
Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice.
Topics: Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Dextroamphetamine; Disease Models, An | 2012 |
Opposite effects of neonatal hypoxia on acute amphetamine-induced hyperlocomotion in adult and adolescent mice.
Topics: Age Factors; Animals; Animals, Newborn; Dextroamphetamine; Disease Models, Animal; Hyperkinesis; Hyp | 2013 |
In vivo amphetamine action is contingent on αCaMKII.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Central Nervous System Stimulants; Cond | 2014 |
Lithium modulates the production of peripheral and cerebral cytokines in an animal model of mania induced by dextroamphetamine.
Topics: Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Brain; Central Nervous System Stimula | 2015 |
Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; De | 2015 |
Mice heterozygous for cathepsin D deficiency exhibit mania-related behavior and stress-induced depression.
Topics: Adaptation, Ocular; Animals; Antidepressive Agents; Bipolar Disorder; Cathepsin D; Corticosterone; D | 2015 |
Neonatal propofol anesthesia modifies activity-dependent processes and induces transient hyperlocomotor response to d-amphetamine during adolescence in rats.
Topics: Analysis of Variance; Animals; Animals, Newborn; Brain; Brain-Derived Neurotrophic Factor; Central N | 2015 |
Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.
Topics: Animals; Brain; Catalepsy; Central Nervous System Stimulants; Cognition; Dextroamphetamine; Drug Des | 2016 |
The d-amphetamine-treated Göttingen miniature pig: an animal model for assessing behavioral effects of antipsychotics.
Topics: Animals; Antipsychotic Agents; Dextroamphetamine; Disease Models, Animal; Dose-Response Relationship | 2009 |
Mice lacking p35 display hyperactivity and paradoxical response to psychostimulants.
Topics: Animals; Central Nervous System Stimulants; Corpus Striatum; Cyclin-Dependent Kinase 5; Dextroamphet | 2010 |
Effects of group exposure on single injection-induced behavioral sensitization to drugs of abuse in mice.
Topics: Animals; Behavior, Animal; Central Nervous System Sensitization; Central Nervous System Stimulants; | 2011 |
Behavioral and neurochemical effects of sodium butyrate in an animal model of mania.
Topics: Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Brain; Butyric Acid; Central Nervous | 2011 |
Influence of stimulant-induced hyperactivity on social approach in the BTBR mouse model of autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Dextroamphetamine; Disease Models, Animal; Dose-Respon | 2013 |
On the role of noradrenaline in psychostimulant-induced psychomotor activity and sensitization.
Topics: Amphetamine-Related Disorders; Animals; Central Nervous System Stimulants; Clonidine; Cocaine; Cocai | 2003 |
[CHANGES INDUCED BY SOME PSYCHOPHARMACOLOGICAL AGENTS IN CIRCULATORY AND NEUROPSYCHIC CONDITIONS DUE TO ENVIRONMENTAL HYPER-PRESSURE].
Topics: Acetates; Atmospheric Pressure; Cardiovascular System; Central Nervous System Stimulants; Cerebrovas | 1963 |
Hyperactivity following postnatal NMDA antagonist treatment: reversal by D-amphetamine.
Topics: Animals; Behavior, Animal; Brain; Central Nervous System Depressants; Central Nervous System Stimula | 2003 |
Long-term social isolation and medial prefrontal cortex: dopaminergic and cholinergic neurotransmission.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucleus; Chromatography, High Pressure Liquid; Dext | 2004 |
A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex?
Topics: Animals; Benzazepines; Chromans; Dextroamphetamine; Dopamine Agents; Dopamine Agonists; Dopamine Ant | 2004 |
Behavioural effects of thieno and pyrazolo [2,1] benzothiazepine derivatives in mice.
Topics: 5-Hydroxytryptophan; Animals; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Apomorphi | 2004 |
Opposite influence of MPEP, an mGluR5 antagonist, on the locomotor hyperactivity induced by PCP and amphetamine.
Topics: Animals; Antipsychotic Agents; Dextroamphetamine; Dopamine Agents; Excitatory Amino Acid Antagonists | 2004 |
The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats.
Topics: Animals; Animals, Newborn; Apomorphine; Body Weight; Corpus Striatum; Dextroamphetamine; Dopamine; D | 2005 |
Dietary cadmium exposure attenuates D-amphetamine-evoked [3H]dopamine release from striatal slices and methamphetamine-induced hyperactivity.
Topics: Animals; Brain; Cadmium; Central Nervous System Stimulants; Dextroamphetamine; Diet; Dopamine; Dopam | 2005 |
Differential involvement of 5-HT projections within the amygdala in prepulse inhibition but not in psychotomimetic drug-induced hyperlocomotion.
Topics: 5,7-Dihydroxytryptamine; Acoustic Stimulation; Amygdala; Animals; Autoradiography; Chromatography, H | 2006 |
CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.
Topics: Amphetamines; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Dextro | 2007 |
Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium.
Topics: Animals; Antimanic Agents; Brain; Central Nervous System Stimulants; Data Interpretation, Statistica | 2007 |
Reduction of corticostriatal glutamatergic fibers in basic fibroblast growth factor deficient mice is associated with hyperactivity and enhanced dopaminergic transmission.
Topics: Actins; Analysis of Variance; Animals; Apomorphine; Cocaine; Dextroamphetamine; Dopamine; Dopamine A | 2007 |
Analogs of SR-141716A (Rimonabant) alter d-amphetamine-evoked [3H] dopamine overflow from preloaded striatal slices and amphetamine-induced hyperactivity.
Topics: Animals; Behavior, Animal; Cocaine; Corpus Striatum; Dextroamphetamine; Dopamine; Dopamine Uptake In | 2007 |
Effect of N-acetylcysteine and/or deferoxamine on oxidative stress and hyperactivity in an animal model of mania.
Topics: Acetylcysteine; Animals; Bipolar Disorder; Central Nervous System Stimulants; Deferoxamine; Dextroam | 2008 |
Central and peripheral effects of lithium on amphetamine-induced hyperactivity in rats.
Topics: Animals; Brain; Chlorides; Dextroamphetamine; Humans; Hyperkinesis; Lithium; Lithium Chloride; Male; | 1981 |
Antagonism by d-amphetamine of trimethyltin-induced hyperactivity evidence toward an animal model of hyperkinetic behavior.
Topics: Animals; Dextroamphetamine; Disease Models, Animal; Humans; Hyperkinesis; Male; Motor Activity; Rats | 1983 |
Thyrotropin-releasing hormone and amphetamine produce different patterns of behavioral excitation in rats.
Topics: Akathisia, Drug-Induced; Animals; Arousal; Brain; Dextroamphetamine; Humans; Hyperkinesis; Male; Rat | 1981 |
Haloperidol-induced hyperactivity in neonatal rats: effect of lithium and stimulants.
Topics: Animals; Animals, Newborn; Dextroamphetamine; Disease Models, Animal; Female; Haloperidol; Humans; H | 1982 |
Hyperkinetic syndrome and Tourette syndrome.
Topics: Adolescent; Child; Dextroamphetamine; Humans; Hyperkinesis; Male; Methylphenidate; Pemoline; Tourett | 1982 |
Dopamine-norepinephrine interaction in hyperactive boys treated with d-amphetamine.
Topics: Age Factors; Body Surface Area; Child; Creatinine; Dextroamphetamine; Dopamine; Drug Interactions; H | 1982 |
Hyperactivity and hyperkinesis.
Topics: Aggression; Animals; Dextroamphetamine; Dogs; Humans; Hyperkinesis | 1980 |
Hyperactivity in developing rats: sex differences in 6-hydroxydopamine and amphetamine effects.
Topics: Animals; Body Weight; Brain Chemistry; Dextroamphetamine; Dopamine; Female; Humans; Hydroxydopamines | 1981 |
Effects of reserpine and amphetamine on the development of hyperactivity in maternally deprived rat pups.
Topics: Animals; Body Temperature; Dextroamphetamine; Dose-Response Relationship, Drug; Heart Rate; Humans; | 1980 |
Tolerance to dextroamphetamine sulfate in hyperactive children: assessment using an empirical neuropsychological paradigm--a pilot study.
Topics: Attention; Child; Dextroamphetamine; Drug Tolerance; Humans; Hyperkinesis; Language; Memory; Motor S | 1980 |
Paradoxical dextroamphetamine response.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Child; Dextroamphe | 1981 |
Paradoxical effects of d-amphetamine upon seizure susceptibility in 2 selectively bred lines of mice.
Topics: Age Factors; Animals; Anticonvulsants; Convulsants; Dextroamphetamine; Disease Models, Animal; Dopam | 1980 |
Dextroamphetamine: cognitive and behavioral effects in normal and hyperactive boys and normal adult males.
Topics: Adult; Behavior; Child; Cognition; Dextroamphetamine; Humans; Hyperkinesis; Male | 1980 |
Cognitive processes in normal and hyperactive children and their response to amphetamine treatment.
Topics: Child; Cognition; Dextroamphetamine; Double-Blind Method; Humans; Hyperkinesis; Male; Mental Recall | 1980 |
Paradoxical response to amphetamine in a hyperkinetic adult.
Topics: Adult; Dextroamphetamine; Humans; Hyperkinesis; Male | 1980 |
Behavior and motor activity response in hyperactive children and plasma amphetamine levels following a sustained release preparation.
Topics: Child; Child, Preschool; Delayed-Action Preparations; Dextroamphetamine; Humans; Hyperkinesis; Male; | 1980 |
Impulsivity and psychoeducational intervention in hyperactive children.
Topics: Adolescent; Age Factors; Behavior Therapy; Child; Dextroamphetamine; Female; Humans; Hyperkinesis; I | 1980 |
Growth disturbances in hyperkinetic children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Growth Disorders; Humans; H | 1980 |
Multimodality treatment. A two-year evaluation of 61 hyperactive boys.
Topics: Achievement; Attention; Child; Dextroamphetamine; Humans; Hyperkinesis; Male; Methylphenidate; Motor | 1980 |
What every psychoanalyst should know about minimal brain dysfunction.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Diagnosis, Different | 1980 |
Blockade of prefronto-cortical alpha 1-adrenergic receptors prevents locomotor hyperactivity induced by subcortical D-amphetamine injection.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Dextroamphetamine; D | 1994 |
Serotonin: a behaviorally active compound in the caudate nucleus of cats.
Topics: Animals; Athetosis; Autonomic Agents; Behavior, Animal; Carbachol; Cats; Caudate Nucleus; Compulsive | 1973 |
The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?
Topics: Animals; Antipsychotic Agents; Brain Chemistry; Catalepsy; Dextroamphetamine; Dopamine Agents; Dopam | 1999 |
Stimulation of metabotropic but not ionotropic glutamatergic receptors in the nucleus accumbens is required for the D-amphetamine-induced release of functional dopamine.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Analgesics, Opioid; Animals; Benz | 2001 |
Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Benzodiazepines; Central Nervous System Stimula | 2001 |
Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter.
Topics: Animals; Brain; Dextroamphetamine; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport | 2001 |
A novel black-hooded mutant rat (ci3) with spontaneous circling behavior but normal auditory and vestibular functions.
Topics: Animals; Animals, Congenic; Auditory Perception; Behavior, Animal; Brain Chemistry; Breeding; Cochle | 2001 |
Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia.
Topics: Animals; Catalepsy; Central Nervous System Stimulants; Clozapine; Dextroamphetamine; Dose-Response R | 2002 |
Plasma levels of d-amphetamine in hyperactive children. Serial behavior and motor responses.
Topics: Child; Child, Preschool; Dextroamphetamine; Half-Life; Humans; Hyperkinesis; Male; Motor Activity; P | 1979 |
Paradoxical effect of amphetamine in an endogenous model of the hyperkinetic syndrome in a hybrid dog: correlation with amphetamine and p-hydroxyamphetamine blood levels.
Topics: Amphetamine; Amphetamines; Animals; Behavior, Animal; Body Temperature; Dextroamphetamine; Disease M | 1979 |
Dopamine-dependent hyperactivity in the rat following manipulation of GABA mechanisms in the region of the nucleus accumbens.
Topics: Amino Acids; Animals; beta-Alanine; Cyclohexanecarboxylic Acids; Dextroamphetamine; Dopamine; Dose-R | 1979 |
The medical treatment of epilepsy: managing side effects of antiepileptic drugs.
Topics: Anticonvulsants; Blood; Cerebellar Ataxia; Child; Child, Preschool; Dextroamphetamine; Drug Eruption | 1979 |
Follow-up survey results of medication used to treat hyperactive school children.
Topics: Child; Dextroamphetamine; Drug Prescriptions; Follow-Up Studies; Humans; Hyperkinesis; Income; Maryl | 1979 |
Gilles de la Tourette's syndrome. Familial occurrence and precipitation by methylphenidate therapy.
Topics: Adult; Child; Dextroamphetamine; Haloperidol; Humans; Hyperkinesis; Male; Methylphenidate; Pedigree; | 1977 |
Hyperactive children: problems, issues and approaches.
Topics: Amphetamines; Behavior Therapy; Child; Child Behavior Disorders; Counseling; Dextroamphetamine; Fami | 1978 |
Urinary MHPG excretion in minimal brain dysfunction and its modification by d-amphetamine.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Glycols; Humans; Hyperkines | 1979 |
The hyperactive child--effects of d-amphetamine.
Topics: Child; Dextroamphetamine; Glycols; Humans; Hyperkinesis; Methoxyhydroxyphenylglycol | 1979 |
The effects of stimulant medication on the growth of hyperkinetic children.
Topics: Adolescent; Body Height; Body Weight; Child Behavior Disorders; Dextroamphetamine; Growth; Growth Di | 1979 |
Norepinephrine metabolism and clinical response to dextroamphetamine in hyperactive boys.
Topics: Central Nervous System; Child; Dextroamphetamine; Humans; Hyperkinesis; Male; Metanephrine; Methoxyh | 1979 |
Clinical and experimental studies of phenytoin-induced hyperkinesias.
Topics: Aged; Animals; Apomorphine; Basal Ganglia; Corpus Striatum; Dextroamphetamine; Disease Models, Anima | 1979 |
Caffeine potentiation of amphetamine: implications for hyperkinesis therapy.
Topics: Animals; Caffeine; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Synergism; Humans; Hype | 1977 |
Questions raised on monoamines in childhood hyperkinesis.
Topics: Child; Dextroamphetamine; Dopamine; Humans; Hyperkinesis; Receptors, Dopamine | 1977 |
Small doses of apomorphine and chronic administration of d-amphetamine reduce locomotor hyperactivity produced by radiofrequency lesions of dopaminergic A10 neurons area.
Topics: Animals; Apomorphine; Dextroamphetamine; Dose-Response Relationship, Drug; Humans; Hyperkinesis; Mal | 1977 |
Animal model for study of hyperkinesis and aggression.
Topics: Aggression; Animals; Dextroamphetamine; Dogs; Humans; Hyperkinesis; Models, Psychological | 1978 |
Changes in the electroencephalogram accompanying the use of stimulant drugs (methylphenidate and dextroamphetamine) in hyperactive children.
Topics: Attention; Child; Child, Preschool; Computers; Dextroamphetamine; Electroencephalography; Evoked Pot | 1977 |
Dextroamphetamine and placebo practice effects on selective attention in hyperactive children.
Topics: Attention; Child; Dextroamphetamine; Discrimination Learning; Drug Evaluation; Humans; Hyperkinesis; | 1978 |
Behavior therapy and withdrawal of stimulant medication in hyperactive children.
Topics: Behavior Therapy; Child; Dextroamphetamine; Humans; Hyperkinesis; Methylphenidate; Parents; Psychiat | 1978 |
Urinary MHPG excretion in the hyperactive child syndrome and the effects of dextroamphetamine [proceedings].
Topics: Child; Dextroamphetamine; Glycols; Humans; Hyperkinesis; Male; Methoxyhydroxyphenylglycol | 1978 |
Plasma d-amphetamine absorption and elimination in hyperactive children.
Topics: Child; Dextroamphetamine; Humans; Hyperkinesis; Intestinal Absorption; Male | 1978 |
Growth hormone, prolactin and cortisol responses and growth patterns in hyperkinetic children treated with dextro-amphetamine. Preliminary findings.
Topics: Child; Dextroamphetamine; Growth; Growth Hormone; Humans; Hydrocortisone; Hyperkinesis; Male; Prolac | 1978 |
The hyperactive child syndrome.
Topics: Child; Dextroamphetamine; Diphenhydramine; Humans; Hyperkinesis; Imipramine; Methylphenidate; Pemoli | 1977 |
Hormone and growth responses in hyperkinetic children on stimulant medication [proceedings].
Topics: Child; Dextroamphetamine; Growth; Growth Hormone; Hormones; Humans; Hydrocortisone; Hyperkinesis; Ma | 1977 |
Sleep disturbance in hyperkinetic children.
Topics: Child; Child, Preschool; Dextroamphetamine; Female; Humans; Hyperkinesis; Male; Methylphenidate; Sle | 1977 |
Methylphenidate (ritalin) and other drugs for treatment of hyperactive children.
Topics: Child; Deanol; Dextroamphetamine; Drug Interactions; Humans; Hyperkinesis; Imipramine; Methylphenida | 1977 |
Childhood depression: an explanation of a behavior disorder of children.
Topics: Antidepressive Agents, Tricyclic; Bipolar Disorder; Child; Child Behavior Disorders; Depression; Dex | 1977 |
The syndrome of childhood hyperactivity. 2.
Topics: Adolescent; Child; Child, Preschool; Dextroamphetamine; Humans; Hyperkinesis; Interpersonal Relation | 1977 |
The medication clinic in the spectrum of children's services.
Topics: Child; Child Health Services; Child, Preschool; Dextroamphetamine; Female; Humans; Hyperkinesis; Mal | 1977 |
Urinary catecholamine metabolites in hyperkinetic boys treated with d-amphetamine.
Topics: Child; Depression, Chemical; Dextroamphetamine; Dose-Response Relationship, Drug; Epinephrine; Homov | 1977 |
Paradoxical response to amphetamine in developing rats treated with 6-hydroxydopamine.
Topics: Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Cognition; Corpus Striat | 1976 |
Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dextroamphetamin | 1976 |
Central monoamines and hyperkinase of childhood.
Topics: Adolescent; Child; Child, Preschool; Dextroamphetamine; Dopamine; Female; Homovanillic Acid; Humans; | 1976 |
The hyperkinetic child syndrome: the need for reassessment.
Topics: Amygdala; Behavior Therapy; Dextroamphetamine; Humans; Hyperkinesis; Methylphenidate; Social Adjustm | 1976 |
[The hyperactive child].
Topics: Child; Counseling; Dextroamphetamine; Humans; Hyperkinesis; Male; Methylphenidate | 1975 |
Nomifensine: a potent dopaminergic agonist of antiparkinson potential.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain; Corpus Striatum; Dextroamphetamine; Dopamine; Hum | 1975 |
Growth rebound after termination of stimulant drugs.
Topics: Adolescent; Body Height; Body Weight; Child; Dextroamphetamine; Female; Humans; Hyperkinesis; Male; | 1975 |
Editorial: The hyperactive child.
Topics: Age Factors; Child; Child Behavior Disorders; Child, Preschool; Chlorpromazine; Dextroamphetamine; H | 1975 |
Medication for hyperkinetic children.
Topics: Administration, Oral; Attention; Child; Dextroamphetamine; Humans; Hyperkinesis; Intelligence; Methy | 1975 |
Hyperactivity in children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Reactive Disorders; Dextroamphetamine; D | 1975 |
Dyslexia.
Topics: Attention; Child; Dextroamphetamine; Dyslexia; Humans; Hyperkinesis; Mental Processes; Mental Recall | 1975 |
Stimulant drug treatment of hyperactive adolescents.
Topics: Adolescent; Age Factors; Child; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Evaluation | 1975 |
The hyperkinetic child.
Topics: Child Behavior Disorders; Dextroamphetamine; Humans; Hyperkinesis; Methylphenidate; School Nursing | 1975 |
Actions of dopaminergic agonists on motor function.
Topics: Amantadine; Animals; Apomorphine; Behavior; Dextroamphetamine; Disease Models, Animal; Dopamine Anta | 1975 |
Dextroamphetamine for epilepsy.
Topics: Adolescent; Adult; Anorexia; Capsules; Child; Child, Preschool; Dextroamphetamine; Drug Evaluation; | 1975 |
Effect of amphetamines in hyperkinetic children: stimulant of sedative? A pilot study.
Topics: Amphetamines; Child; Child, Preschool; Dextroamphetamine; Female; Galvanic Skin Response; Humans; Hy | 1975 |
The learning-disabled or hyperactive child: diagnosis and treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Dextroamphetamine; H | 1975 |
Stimulant drugs for hyperactivity: some additional disturbing questions.
Topics: Attention; Child; Civil Rights; Dextroamphetamine; Drug Evaluation; Family Therapy; Humans; Hyperkin | 1976 |
Sequential withdrawal of stimulant drugs and use of behavior therapy with two hyperactive boys.
Topics: Amphetamine; Behavior Therapy; Child; Dextroamphetamine; Humans; Hyperkinesis; Male; Methylphenidate | 1976 |
Current medical practice and hyperactive children.
Topics: Attitude of Health Personnel; Child; Child Behavior; Child Psychiatry; Counseling; Dextroamphetamine | 1976 |
Letter: The hyperkinetic child.
Topics: Child; Dextroamphetamine; Ethics, Medical; Humans; Hyperkinesis; Methylphenidate | 1976 |
Antihistaminics enhance morphine-, but not amphetamine- and scopolamine-induced hyperactivity in mice.
Topics: Animals; Chlorpheniramine; Dextroamphetamine; Diphenhydramine; Drug Synergism; Histamine H1 Antagoni | 1987 |
The role of methylphenidate and dextroamphetamine in hyperactivity in children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Developmental Disabilities; Dextroamphetamine; | 1971 |
The interplay of biological and environmental factors in a preschool-age patient with Klinefelter's syndrome. Case report.
Topics: Abnormalities, Drug-Induced; Amobarbital; Child Behavior Disorders; Child, Preschool; Dermatoglyphic | 1973 |
The adolescent with a learning problem. The need for insight.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Community Mental Health Serv | 1973 |
Drug treatment of hyperactivity in children.
Topics: Age Factors; Child; Dextroamphetamine; Electroencephalography; Humans; Hyperkinesis; Imipramine; Met | 1973 |
Multimodality treatment of the hyperkinetic child.
Topics: Antidepressive Agents; Behavior Therapy; Counseling; Curriculum; Dextroamphetamine; Family Therapy; | 1974 |
Lithium and alpha-methyl-p-tyrosine prevent "manic" activity in rodents.
Topics: Animals; Bipolar Disorder; Chlordiazepoxide; Dextroamphetamine; Disease Models, Animal; Drug Combina | 1974 |
Effects of dextroamphetamine sulfate on EEG sleep patterns of hyperactive children.
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Electroencephalogr | 1971 |
Discussion of case-control study of Hodgkin's disease.
Topics: Amphetamine; Antigens, Viral; Dextroamphetamine; Epidemiologic Methods; Genotype; Herpesvirus 4, Hum | 1974 |
Drugs in management of hyperkinetic and perceptually handicapped children.
Topics: Anticonvulsants; Central Nervous System Stimulants; Child; Child, Preschool; Chlordiazepoxide; Chlor | 1968 |
Type and prevalence of medication used in the treatment of hyperactive children.
Topics: Child; Child Behavior Disorders; Chlorpromazine; Dextroamphetamine; Diphenhydramine; Education, Spec | 1974 |
Letter: "High activity and hyperactivity'.
Topics: Child; Depression; Dextroamphetamine; Humans; Hyperkinesis | 1974 |
Symposium: behavior modification by drugs. 3. The clinical use of stimulant drugs in children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Feeding and Eat | 1972 |
Amphetamine-type drugs for hyperactive children.
Topics: Appetite; Attention Deficit Disorder with Hyperactivity; Body Weight; Brain; Child; Dextroamphetamin | 1972 |
Hyperactive children.
Topics: Adolescent; Child; Child Behavior Disorders; Child, Preschool; Dextroamphetamine; Humans; Hyperkines | 1973 |
Hyperactive children.
Topics: Adolescent; Butyrophenones; Child; Dextroamphetamine; Humans; Hyperkinesis; Methylphenidate | 1973 |
Oral medications for minimal brain dysfunction in children.
Topics: Administration, Oral; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Child Behav | 1973 |
Hyperactive children.
Topics: Brain; Child; Dextroamphetamine; Humans; Hyperkinesis; Methylphenidate; Substance-Related Disorders | 1973 |
Factors influencing the suppressant effects of two stimulant drugs on the growth of hyperactive children.
Topics: Analysis of Variance; Body Height; Body Weight; Child; Dextroamphetamine; Growth Disorders; Humans; | 1973 |
Side effects of methylphenidate.
Topics: Brain Damage, Chronic; Child; Child Behavior Disorders; Delusions; Dextroamphetamine; Evaluation Stu | 1973 |
The making of a myth.
Topics: Age Factors; Child; Dextroamphetamine; Humans; Hyperkinesis; Methylphenidate; Sulfates | 1973 |
Letter: Biochemical aspects of sensitivity reactions.
Topics: Biogenic Amines; Brain; Child; Child, Preschool; Dextroamphetamine; Drug Hypersensitivity; Humans; H | 1973 |
Predicting amphetamine response in hyperkinetic children by electronic pupillography.
Topics: Adolescent; Arousal; Behavior; Child; Child, Preschool; Dextroamphetamine; Female; Humans; Hyperkine | 1973 |
The hyperkinetic syndrome.
Topics: Birth Order; Child; Child Behavior Disorders; Child, Preschool; Dextroamphetamine; Female; Humans; H | 1973 |
Letter: Alternating caffeine and stimulants.
Topics: Caffeine; Child, Preschool; Coffee; Dextroamphetamine; Humans; Hyperkinesis; Male | 1974 |
Dexedrine dyskinesia: an unusual iatrogenic tic.
Topics: Child; Dextroamphetamine; Diagnosis, Differential; Humans; Hyperkinesis; Iatrogenic Disease; Male; M | 1974 |
Letter: The misuse of statistics (continued).
Topics: Child; Dextroamphetamine; Growth; Humans; Hyperkinesis; Statistics as Topic | 1974 |
Lead-induced behavioral dysfunction: an animal model of hyperactivity.
Topics: Amphetamine; Animals; Chloral Hydrate; Dextroamphetamine; Disease Models, Animal; Female; Humans; Hy | 1974 |
A behavior rating scale for assessing improvement in behaviorally deviant children: a preliminary investigation.
Topics: Adolescent; Aggression; Anxiety; Attention; Child; Child Behavior Disorders; Dextroamphetamine; Diag | 1972 |
A 5-year follow-up study of 91 hyperactive school children.
Topics: Adolescent; Child; Chlorpromazine; Cognition Disorders; Dextroamphetamine; Female; Follow-Up Studies | 1972 |
Dissociation of learning on stimulant-drug therapy.
Topics: Amphetamine; Animals; Antidepressive Agents; Child; Dextroamphetamine; Humans; Hyperkinesis; Learnin | 1972 |
Mood-altering drugs and hyperkinetic children.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Child; Child Behavior Disorder | 1972 |
Hyperactivity in children: types, diagosis, drug therapy, approaches to management.
Topics: Amphetamine; Anxiety; Attention; Attention Deficit Disorder with Hyperactivity; Brain Damage, Chroni | 1972 |
Athetoid and choreiform hyperkinesias produced by caudate application of dopamine in cats.
Topics: Animals; Athetosis; Behavior, Animal; Cats; Caudate Nucleus; Chorea; Dextroamphetamine; Dihydroxyphe | 1972 |
Electrodermal correlates of hyperactivity in children.
Topics: Arousal; Child; Child Behavior Disorders; Dextroamphetamine; Galvanic Skin Response; Humans; Hyperki | 1971 |
Lithium attenuates drug-induced hyperactivity in rats.
Topics: Animals; Chlordiazepoxide; Defecation; Dextroamphetamine; Female; Humans; Hyperkinesis; Lithium; Mot | 1971 |
Review of stimulant drugs in learning and behavior disorders.
Topics: Aggression; Amphetamine; Child; Child Behavior Disorders; Dextroamphetamine; Humans; Hyperkinesis; L | 1971 |
Photic responses in hyperkinesis of childhood.
Topics: Adult; Brain; Child; Child, Preschool; Dextroamphetamine; Electroencephalography; Humans; Hyperkines | 1971 |
Playroom observations of hyperactive children on medication.
Topics: Child; Child Behavior; Child, Preschool; Chlorpromazine; Dextroamphetamine; Evaluation Studies as To | 1971 |
The emergence of neurotic conflict in some children after successful administration of dextroamphetamine.
Topics: Attitude of Health Personnel; Attitude to Health; Child; Child, Preschool; Conflict, Psychological; | 1969 |
Treatment of hyperactivity in children.
Topics: Child; Chlorpromazine; Dextroamphetamine; Female; Humans; Hyperkinesis; Male; Methylphenidate; Thior | 1970 |
Treatment of hyperkinetic child with dextroamphetamine and ephedrine.
Topics: Asthma; Dextroamphetamine; Ephedrine; Headache; Humans; Hyperkinesis | 1970 |
Pediatric practice: whose mood are we altering?
Topics: Child; Child Behavior Disorders; Dextroamphetamine; Humans; Hyperkinesis; Male; Methylphenidate | 1971 |
Dextroamphetamine, catecholamines, and behavior. The effect of dextroamphetamine in retarded children.
Topics: Catecholamines; Child; Child Behavior Disorders; Dextroamphetamine; Dopamine; Epinephrine; Humans; H | 1969 |